Masato Hosokawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8319417/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prion-like spreading of pathological α-synuclein in brain. Brain, 2013, 136, 1128-1138.	7.6	691
2	Pathological alpha-synuclein propagates through neural networks. Acta Neuropathologica Communications, 2014, 2, 88.	5.2	203
3	The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	182
4	Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Human Molecular Genetics, 2017, 26, ddx011.	2.9	110
5	Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology, 2010, 30, 170-181.	1.2	109
6	Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain, 2012, 135, 3380-3391.	7.6	95
7	Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia, 2003, 42, 417-423.	4.9	83
8	Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice. PLoS ONE, 2012, 7, e52389.	2.5	79
9	A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human α-synuclein A30P + A53T transgenic mice. Parkinsonism and Related Disorders, 2009, 15, 649-654.	2.2	72
10	Natural killer cells of Parkinson's disease patients are set up for activation: A possible role for innate immunity in the pathogenesis of this disease. Parkinsonism and Related Disorders, 2008, 14, 46-51.	2.2	59
11	Progranulin Reduction Is Associated With Increased Tau Phosphorylation in P301L Tau Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 158-165.	1.7	46
12	$\hat{I}\pm$ -synuclein strains that cause distinct pathologies differentially inhibit proteasome. ELife, 2020, 9, .	6.0	45
13	Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. Acta Neuropathologica, 2012, 124, 383-394.	7.7	40
14	Microsomal prostaglandin E synthaseâ€1 is induced in alzheimer's disease and its deletion mitigates alzheimer's diseaseâ€like pathology in a mouse model. Journal of Neuroscience Research, 2013, 91, 909-919.	2.9	39
15	C9ORF72 dipeptide repeat poly-GA inclusions promote intracellular aggregation of phosphorylated TDP-43. Human Molecular Genetics, 2018, 27, 2658-2670.	2.9	39
16	Novel virus discovery in field-collected mosquito larvae using an improved system for rapid determination of viral RNA sequences (RDV ver4.0). Archives of Virology, 2009, 154, 153-158.	2.1	35
17	Familial ALS with FUS P525L mutation: two Japanese sisters with multiple systems involvement. Journal of the Neurological Sciences, 2012, 323, 85-92.	0.6	33
18	Longâ€ŧerm oral intake of aluminium or zinc does not accelerate Alzheimer pathology in AβPP and AβPP/tau transgenic mice. Neuropathology, 2012, 32, 390-397.	1.2	33

MASATO HOSOKAWA

#	Article	IF	CITATIONS
19	Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation. Scientific Reports, 2017, 7, 1513.	3.3	33
20	Distinct pathways leading to TDP-43-induced cellular dysfunctions. Human Molecular Genetics, 2014, 23, 4345-4356.	2.9	30
21	Tau accumulation in the nucleus accumbens in tangle-predominant dementia. Acta Neuropathologica Communications, 2014, 2, 40.	5.2	29
22	Differential diagnosis of amyotrophic lateral sclerosis from Guillain–Barré syndrome by quantitative determination of TDP-43 in cerebrospinal fluid. International Journal of Neuroscience, 2014, 124, 344-349.	1.6	26
23	Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants. Scientific Reports, 2016, 6, 33479.	3.3	21
24	The Abundance of Nonphosphorylated Tau in Mouse and Human Tauopathy Brains Revealed by the Use of Phos-Tag Method. American Journal of Pathology, 2016, 186, 398-409.	3.8	20
25	Early-life stress induces the development of Alzheimer's disease pathology via angiopathy. Experimental Neurology, 2021, 337, 113552.	4.1	17
26	Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2. Acta Neuropathologica Communications, 2021, 9, 182.	5.2	17
27	Comparative study to elucidate the mechanism underlying the difference in airway hyperresponsiveness between two mouse strains. International Immunopharmacology, 2007, 7, 1852-1861.	3.8	16
28	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice. Experimental Animals, 2018, 67, 63-70.	1.1	14
29	Familial British dementia: colocalization of furin and ABri amyloid. Acta Neuropathologica, 2003, 106, 278-284.	7.7	12
30	Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms. Brain, 2022, 145, 349-361.	7.6	11
31	Effects of progranulin on the pathological conditions in experimental myocardial infarction model. Scientific Reports, 2020, 10, 11842.	3.3	10
32	Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2016, 4, 36.	5.2	9
33	Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration. Psychogeriatrics, 2018, 18, 307-312.	1.2	7
34	Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs. Journal of Neuroinflammation, 2004, 1, 17.	7.2	6
35	Inhibition of HIV-1 infection in cells expressing an artificial complementary peptide. Biochemical and Biophysical Research Communications, 2004, 324, 236-240.	2.1	6
36	Pathological features of FTLD-FUS in a Japanese population: Analyses of nine cases. Journal of the Neurological Sciences, 2013, 335, 89-95.	0.6	6

MASATO HOSOKAWA

#	Article	IF	CITATIONS
37	Dextran sulphate-induced tau assemblies cause endogenous tau aggregation and propagation in wild-type mice. Brain Communications, 2020, 2, fcaa091.	3.3	6
38	Pyriproxyfen enhances the immunoglobulin G immune response in mice. Microbiology and Immunology, 2013, 57, 316-322.	1.4	4
39	Atypical FTLDâ€FUS associated with ALSâ€TDP: A case report. Neuropathology, 2013, 33, 83-86.	1.2	3
40	Enhancement and regulation effect of myrcene on antibody response in immunization with ovalbumin and Ag85B in mice. Asian Pacific Journal of Allergy and Immunology, 2017, 34, 314-323.	0.4	3
41	Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model. Pharmaceutics, 2022, 14, 815.	4.5	3
42	Human IgM Monoclonal Antibodies Reactive with HIVâ€1â€Infected Cells Generated Using a Transâ€Chromosome Mouse. Microbiology and Immunology, 2005, 49, 447-459.	1.4	2
43	An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. Neuropathology, 2015, 35, 280-288.	1.2	2
44	Progranulin and Frontotemporal Lobar Degeneration. , 2019, , 35-69.		2
45	Therapeutic effect of anti-HMCB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator. NeuroReport, 2022, 33, 297-303.	1.2	2
46	LC–MS/MS assay for the investigation of acetylated Alpha-synuclein in serum from postmortem Alzheimer's disease pathology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1181, 122885.	2.3	1
47	P3â€300: Phosphorylated TAU and Alphaâ€Synuclein Accumulation in Familial Granulin Mutation Cases. Alzheimer's and Dementia, 2016, 12, P956.	0.8	0

48 PGRN and Neurodegenerative Diseases Other Than FTLD., 2019, , 71-84.

0